Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of a bivalent Shigella conjugate vaccine in children aged 6 months to 5 years in China
CTR20213055Phase 3Active
- Sponsor
- Beijing Luzhu Biotechnology
- Start
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Shigella flexneri-sonnei bivalent conjugate vaccine in shigellosis, sponsored by Beijing Luzhu Biotechnology. Started Dec 2021; status: active.
02
Drugs
Shigella flexneri-sonnei bivalent conjugate vaccine
03
Conditions
shigellosis
Beyond the preview
Go deeper on CTR20213055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213055.